Asahi Kasei's New Hope for Kidney Disease Enters Human Trials

TOKYO, JAPAN – February 18, 2026 – Asahi Kasei Pharma, in collaboration with biotech partner Alchemedicine, has initiated a Phase I clinical study for AK1960, a novel drug candidate aimed at diseases that resist standard therapies. The move marks a critical first step in human testing for a compound that holds promise for patients with refractory chronic kidney disease (CKD), a condition with significant unmet medical needs.

The advancement of AK1960 from successful animal studies into a formal human trial represents a key milestone for the Japanese pharmaceutical company and its strategic pivot towards high-impact, specialty medicines. The drug, an Endothelin A (ETA) receptor antagonist, targets a biological pathway implicated in the progression of severe kidney damage.

A New Attack on a Stubborn Disease

Chronic Kidney Disease affects millions globally, often driven by diabetes and hypertension. While treatments like blood pressure medications and newer SGLT2 inhibitors have improved care, a substantial number of patients have "refractory" disease, meaning their condition continues to worsen despite the best available therapies. These individuals face a grim trajectory towards dialysis or transplantation.

AK1960 aims to intervene through a well-known but challenging pathway. It is designed to block the Endothelin A (ETA) receptor, which is activated by a potent peptide called Endothelin-1 (ET-1). When ET-1 binds to ETA receptors on blood vessel walls, it causes vasoconstriction, inflammation, and fibrosis—a trio of effects that are particularly damaging to kidneys over time. By blocking this receptor, ETA antagonists can theoretically protect the organ from this harmful cascade.

The concept is not entirely new. The drug class has seen success in treating pulmonary arterial hypertension, and more recently, dual-action drugs like sparsentan, which targets both the endothelin and angiotensin receptors, have been approved for specific kidney conditions. However, Asahi Kasei highlights AK1960's high selectivity for the ETA receptor. This specificity is crucial, as earlier-generation ETA antagonists have been associated with side effects like fluid retention and liver toxicity. A more selective compound could potentially offer a better safety profile, making it a more viable option for a broader population of CKD patients.

The Power of a Novel Platform

The unique structure of AK1960 originates from Alchemedicine’s HiSAP™ medicinal chemistry platform. This technology is designed to rapidly generate novel small molecules by building from a library of over 35,000 proprietary core scaffolds. The goal is to overcome common drug development hurdles like poor solubility or off-target effects that can derail promising compounds.

In a field where discovering truly new chemical structures is a monumental task, platforms like HiSAP™ represent a vital source of innovation. By providing a new starting point for drug design, it allowed for the creation of AK1960's unique molecular foundation. According to the companies, this new structure is what enables its potent and selective inhibition of the ETA receptor, which was demonstrated in preclinical animal models of kidney disease.

The partnership, which began with an exclusive license agreement in 2022 giving Asahi Kasei worldwide rights, exemplifies a modern pharmaceutical strategy: larger companies tapping into the specialized innovation engines of smaller biotech firms to fuel their pipelines with cutting-edge science.

A Calculated Global Strategy

The development of AK1960 is not an isolated event but a cornerstone of Asahi Kasei's declared 'First Priority' business strategy for its pharmaceutical division. The company is aggressively building a global presence in specialty therapeutic areas, with a clear focus on nephrology.

This strategy is underscored by its recent acquisitions. The global development and commercialization of AK1960 will be supported by Calliditas Therapeutics AB and Veloxis Pharmaceuticals, Inc., two companies now under the Asahi Kasei umbrella. Each brings critical, specialized expertise.

Calliditas is the developer of TARPEYO®, a targeted therapy for IgA nephropathy, a rare form of CKD. Their experience in navigating the clinical and regulatory pathways for a novel kidney drug is invaluable. Veloxis focuses on transplant medicine, providing deep expertise in caring for patients with end-stage kidney disease. Together, these companies form a powerful nephrology-focused ecosystem, providing Asahi Kasei with the infrastructure and knowledge to develop and potentially launch a major kidney drug on a global scale.

“The advancement of AK1960 into a Phase I study reflects an important milestone for Asahi Kasei Pharma and demonstrates our close collaboration with Alchemedicine to address unmet medical needs,” said Yasuo Nakamura, Director and Senior Executive Officer at Asahi Kasei Pharma, in the original announcement. “By leveraging the expertise of Calliditas and Veloxis in therapeutic development, we will continue advancing AK1960.”

The Long Road from Lab to Pharmacy

While the initiation of a Phase I trial is a moment of significant scientific and corporate achievement, it also marks the beginning of a long, expensive, and uncertain road. Phase I trials are the first gate in the human testing process, designed primarily to evaluate the safety, tolerability, and pharmacokinetic profile of a new drug in a small number of participants.

The historical odds are daunting. Industry-wide data suggests that only about 7-10% of drugs that enter Phase I clinical trials ultimately receive market approval. The journey from this initial stage to a pharmacy shelf is a marathon, not a sprint, typically taking a decade or more and costing hundreds of millions, if not billions, of dollars.

Following a successful Phase I, AK1960 would need to proceed to Phase II trials to assess its efficacy in patients with kidney disease, and then to much larger, more definitive Phase III trials to confirm its benefits and safety against a placebo or standard of care. Each step carries a high risk of failure. For patients, researchers, and investors, the advancement of AK1960 is a crucial step forward, but it is the first of many that will be required to turn this promising molecule into a proven medicine.